Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) shares gapped down prior to trading on Thursday . The stock had previously closed at $7.15, but opened at $5.94. Oxford BioMedica shares last traded at $5.83, with a volume of 2,675 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, Zacks Research upgraded Oxford BioMedica to a “hold” rating in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.
Read Our Latest Research Report on OXBDF
Oxford BioMedica Price Performance
About Oxford BioMedica
Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.
In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.
Read More
- Five stocks we like better than Oxford BioMedica
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
